Laurus Labs zooms 128% from March low; hits new high in weak market
Laurus Labs set out an expansion in a quarterly results development for Q2FY27.
· Business Standard Mkts
Laurus Labs Q2 outlook: On the EBITDA front, analysts at Kotak Institutional Equities build in 67% YoY growth to ₹680 crore in Q2FY27 with EBITDA margin expansion of 680 bps to 31.2%.
Key facts
- Period
- Q2FY27
The analysis
Laurus Labs reported ₹680 crore for Q2FY27, with movement of 67%, 128% and 31.2% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.4% on the day at ₹2,068.60, and has returned +35.4% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved -3.8% over the same period, so Laurus Labs is running 39.2 points ahead of its peers.
For Laurus Labs, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- The company directly in focus is LAURUSLABS.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads positive.
In this story
Related coverage
Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players
Solara Active Pharma share price zooms 16% on Q2 turnaround; H1 net up 103x
PVR Inox among 4 stocks hitting 52-week highs; rallied up to 13% in a month
Central Bank of India Q2 profit rises 21% as loans grow 30%
Moody's revises IPO-bound Oyo parent Prism's outlook to 'positive'